Abstract
Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling. Novel investigational anti-IgE monoclonal antibodies with improved pharmacodynamic properties are in the pipeline, potentially offering alternative mechanisms of modulating IgE pathway.
The aim of this review is to update current knowledge on anti-IgE therapy in pediatric respiratory diseases.
Keywords: Allergic rhinitis, asthma, IgE, ligelizumab, MEDI4212, omalizumab, quilizumab, rhinosinusitis.
Graphical Abstract
Related Journals
49
1
1